Kapil Kumar Goel^¹*, Asmita Gajbhiye , Anu^² and  Nidhi M. Goel^³

^¹Faculty of Ayurved and Medical Sciences (Pharmacy), Gurukul Kangri Vishwavidyalaya, Haridwar.

^²Department of Pharmacy, Bharat Institute of Technology, Meerut .

^³Department of Pharmaceutical Sciences, S.G.R.R.I.T.S, Dehradun .

⁴Department of Pharmaceutical Sciences, Dr. Harisingh Gour Vishwavidyalaya Sagar.

Abstract

The present work to investigate the newer antibacterial and antifungal Agents with less side effect and potent activity.In the present work, a series of 2,6-diaryl-3-methyl-4-piperidones were synthesized by Mannich reaction (condensation) of ethyl methyl ketone, benzaldehyde, substituted aromatic aldehydes and ammonium acetate. Thiosemicarbazone derivatives of 2,6-diaryl-3-methyl-4-piperidones were synthesized by reaction of 2,6-diaryl-3-methyl-4-piperidones with thiosemicarbazide. All the title compounds have been screened for their in vitro antibacterial activity against various strains. Some of these title compounds exhibited significant antimicrobial activity (compared with ampicillin) and antifungal activity (compared with terbinafine). The present study reveals that these compounds could be used as a template for the future development through modification or derivatization to design more potent antimicrobial agents.

Keywords

Piperidin-4-one; Thiosemicarbazone; Antibacterial agents; Antifungal agents

Download this article as: 

Copy the following to cite this article: Goel K. K , Gajbhiye A , Anu and Goel N. M. Synthesis and Antimicrobial Activity of Piperidin-4-one Derivatives. Biomed Pharmacol J 2008;1(1).

Copy the following to cite this URL: Goel K. K , Gajbhiye A , Anu and Goel N. M. Synthesis and Antimicrobial Activity of Piperidin-4-one Derivatives. Biomed Pharmacol J 2008;1(1). Available from: http://biomedpharmajournal.org/?p=324

Introduction

Infection is a major category of human disease and skilled management of antimicrobial drugs is of first importance. The spread of antimicrobial resistance among pathogenic bacteria has become a serious problem for the clinical management of infectious diseases and has resulted in a clear need for novel antimicrobial agents other than analogs of existing antibiotics¹. Among the wide variety of heterocycles that have been explored for developing pharmaceutically important molecules, Piperidin-4-ones exhibit various biological activities like analgesic, hypotensive and central nervous system depressant, antiviral, bactericidal and fungicidal activities^2,3,4,5. The present work was undertaken with a view to explore the possibility of antibacterial and antifungal activities in a piperidine ring having a thiosemicarbazone moiety.

Syntheses of title compounds were affected as outlined in the Scheme I. Ammonium acetate, benzaldehyde, 4-alkylbenzaldehyde and 2-butanone in ethanol were condensed to form 3-alkyl-2-(4’-aryl)-6-phenylpiperidin-4-ones (1a-6a)^6,7. The respective ketone thiosemicarbazone (1b-6b) were prepared in good yields by condensing thiosemicarbazides with appropriate ketones, in the presence of trace amounts of conc. HCl. These were characterized by physical properties, IR and ^1HNMR spectral studies. The antimicrobial activities of the compounds were carried out according to the standard procedures.

Scheme 1: Thiosemicarbazone derivatives of 2,6-diaryl-3-methyl-4-piperidones Click here to View scheme

 

Material and Methods

Ammonium acetate, benzaldehyde, 4-alkyl benzaldehyde and ethanol were obtained from SD Fine Chemicals Pvt. Ltd., Boisar. Thiosemicarbazide were obtained from E. Merck Ltd., Mumbai.

The melting points were carried out in an open capillary tube and were uncorrected. Thin layer chromatography was performed using silica gel coated on a glass plate and spots were visualized by exposure to iodine vapor. IR spectra in Nujol were recorded on a Shimadzu IR spectrophotometer. ¹H NMR spectra were recorded in DMSO on an av500 spectrometer using TMS as an internal standard (chemical shifts in δ ppm).

Synthesis of 3-alkyl-2-(4’-aryl)-6-phenylpiperidin-4-ones (1a-6a)

Dry ammonium acetate (0.1 moles) was dissolved in 50 ml ethanol and the solution was mixed with 4-alkyl benzaldehyde (0.1 moles), benzaldehyde (0.1 moles) and butane-2-one (0.1 moles). The mixture was heated to boiling and allowed to stand at room temperature overnight. Then 30 ml conc. HCl was added and the precipitated hydrochloride salt was collected, washed with mixture of ethanol and ether (1: 5). A suspension of the hydrochloride salt in acetone was treated with strong liquid ammonia and the free base was obtained by separating water. The crude product was recrystallised from ethanol to get the compound and thin layer chromatography was eluted in methanol: ethyl acetate.

2-[4-(dimethylamino) phenyl]-3-methyl-6-phenylpiperidin-4-one (Compound 1a): Yield-82.38%, m.p.– 188-190⁰C, Rf- 0.60, IR (KBr): 3426, 3039, 2936, 1722, 1459, 749 cm^-1, ¹H-NMR (DMSO-d₆): d 7.4-7.7 (9H), 4.3-4.9(1H), 0.95(3H), 2.3-2.6(6H).

2-(4-methoxyphenyl)-3-methyl-6-phenylpiperidin-4-one (Compound 2a): Yield-80.33%, m.p.–170-172⁰C, Rf- 0.76, IR (KBr): 3230,2876,1650,1210 cm^-1.

2-(4-hydroxyphenyl)-3-methyl-6-phenylpiperidin-4-one (Compound 3a): Yield-69.39%, m.p.–154-156⁰C, Rf- 0.87, IR (KBr): 3256, 2976, 1719, 1457,1219 cm^-1, ¹H-NMR (DMSO-d₆): d 7.4-7.7 (5H), 6.8-6.9(4H), 4.8(1H), 2.8(2H), 2.0-2.1(1H).

2-[4-(dimethylamino)phenyl]-3-isopropyl-6-phenylpiperidin-4-one (Compound 4a): Yield-72.32%, m.p.–196-198⁰C, Rf- 0.57, IR (KBr): 3200, 2957,1702, 1458,1492 cm^-1, ¹H-NMR (DMSO-d₆): d 7.2-7.5 (9H), 4.1(1H), 2.7-2.8(2H), 2.4-2.5(6H), 0.8-1.0(6H).

3-isopropyl-2-(4-methoxyphenyl)-6-phenylpiperidin-4-one (Compound 5a ): Yield-59.44%, m.p.–184-186⁰C, Rf- 0.67, IR (KBr): 3134, 1631, 1403,699 cm^-1, ¹H-NMR (DMSO-d₆): d 7.0-7.7 (9H), 4.6-4.8(1H), 3.8(3H), 2.9(1H),1.0-1.1(6H).

2-(4-hydroxyphenyl)-3-isopropyl-6-phenylpiperidin-4-one (Compound 6a): Yield-63.43%, m.p.–160-162⁰C, Rf- 0.83, IR (KBr): 3234, 1756, 1250 cm^-1.

Synthesis of 3-alkyl-2-(4’-aryl)-6-phenyl piperidin-4-thiosemicarbazones (1b-6b)

To a boiling solution of compounds 1a-6a (0.01 moles) in 45 ml methanol, added a few drops of conc. HCl. Thereafter thiosemicarbazide (previously dissolved in    20 ml methanol) solution (0.01 moles) was added dropwise with stirring. The reaction mixture was refluxed for 3 hour on a heating mentle. After cooling, the solid product was filtered off and recrystalised from 20 ml methanol to get compound and thin layer chromatography was eluted in methanol: ethyl acetate.

2-[4-(dimethylamino) phenyl]-3-methyl-6-phenylpiperidin-4-thiosemicarbazone (Compound 1b): Yield-68.26%, m.p.–230-232⁰C, Rf- 0.38, IR (KBr): 3424, 3101, 2954, 1207-1082,1627 cm^-1.

2-(4-methoxyphenyl)-3-methyl-6-phenylpiperidin-4- thiosemicarbazone (Compound 2b): Yield-59.78%, m.p.–222-224⁰C, Rf- 0.93, IR (KBr): 3430, 3168, 1630, 691cm^-1, ¹H-NMR (DMSO-d₆): d 7.0-7.4(9H), 4.5-4.7(1H), 3.8-3.3(3H), 1.5-0.8(3H).

2-(4-hydroxyphenyl)-3-methyl-6-phenylpiperidin-4-thiosemicarbazone (Compound 3b): Yield-48.02%, m.p.–218-220⁰C, Rf- 0.65, IR (KBr): 3150,2926, 1178-1063, 1457,1226,697 cm^-1.

2-[4-(dimethylamino)-phenyl]-3-isopropyl-6-phenylpiperidin-4-thiosemicarbazone                                                     (Compound 4b): Yield-39.11%, m.p.–248-250⁰C, Rf- 0.35, IR (KBr): 3423, 2927-2812, 1149-1122, 1459, 649 cm^-1.

3-isopropyl-2-(4-methoxyphenyl)-6-phenylpiperidin-4-thiosemicarbazone (Compound 5b): Yield-45.22%, m.p.–238-240⁰C, Rf- 0.38, IR (KBr): 3150, 2953, 1452, 1210-1150 cm^-1, ¹H-NMR (DMSO-d₆): d 7.5(5H), 6.3-6.5(4H), 2.0-2.1(1H).

2-(4-hydroxyphenyl)-3-isopropyl-6-phenylpiperidin-4-thiosemicarbazone (Compound 6b): Yield-39.26%, m.p.–228-230⁰C, Rf- 0.42, IR (KBr): 3256, 2976, 1457, 1219,657 cm^-1.

Table 1: Spectral Data of Compounds 1a to 6b

Compound	IR (cm-1)	1HNMR (d ppm)
1a   2a   3a   4a   5a   6a 1b   2b   3b   4b   5b 6b	3426, 3039,2936,1722, 1459,749   3230,2876,1650,1210   3256, 2976, 1719, 1457, 1401, 1219 3200, 2957,1702, 1458, 1492   3134, 1631, 1403,699   3234,1756,1250 3424, 3101, 2954, 1207-1082, 1627 3430, 3168, 1630,691   3150, 2926, 1178-1063, 1457, 1226, 697 3423, 2927-2812, 1149-1122, 1459,649 3150, 2953, 1452,1210-1150 3256, 2976, 1457, 1219,657	7.4-7.7 (9H), 4.3-4.9(1H), 0.95(3H), 2.3-2.6(6H) —–   7.4-7.7 (5H), 6.8-6.9(4H), 4.8(1H), 2.8(2H), 2.0-2.1(1H) 7.2-7.5 (9H), 4.1(1H), 2.7-2.8(2H), 2.4-2.5(6H), 0.8-1.0(6H) 7.0-7.7 (9H), 4.6-4.8(1H), 3.8(3H), 2.9(1H), 1.0-1.1(6H) —- —–   7.0-7.4(9H), 4.5-4.7(1H), 3.8-3.3(3H), 1.5-0.8(3H) —-   —-   7.5(5H), 6.3-6.5(4H), 2.0-2.1(1H) —-

 

Antibacterial activity

The synthesized derivatives 1a-6b were screened for their in vitro antibacterial activity against Staphylococcus aureus (ATCC 6538), Escherichia coli (ATCC 8739), Bacillus subtilis (MTCC-441), using disk diffusion method. Mueller-Hinton agar (Difco, Detroit, USA) was used for the bacterial strains. All compounds have shown good activity. MIC values of the compounds are given in Table 2 and 3.

Table 2: Antibacterial activity: MIC values (µg/mL) of compounds (1a-6a)

Compd	R	R’	S. aureus ATCC 6538	E. coli ATCC 8739	B. subtilis MTCC 441
1a	CH3	N(CH3)2	12	8	10
2a	CH3	OCH3	12	6	15
3a	CH3	OH	17	4	13
4a	CH(CH3)2	N(CH3)2	10	4	13
5a	CH(CH3)2	OCH3	10	5	17
6a	CH(CH3)2	OH	16	6	15
Ampicillin			22	10	23

 

Table 3: Antibacterial activity: MIC values (µg/mL) of compounds (1b-6c)

Compd	R	R’	S. aureus ATCC 6538	E. coli ATCC 8739	B. subtilis MTCC 441
1b	CH3	N(CH3)2	8	8	14
2b	CH3	OCH3	11	6	13
3b	CH3	OH	15	4	14
4b	CH(CH3)2	N(CH3)2	10	3	14
5b	CH(CH3)2	OCH3	12	6	13
6b	CH(CH3)2	OH	15	5	13
Ampicillin			22	10	23

Antifungal activity

Study Design

Micro dilution was used according to a standard protocol described by the NCCLS^{10, 11}. Five strains were tested each of the following species: Microsporum gypseum NCPF-580, Microsporum canis, Trichophyton mentagrophytes, Trichophyton rubrum and Candida albicans ATCC 10231.

Medium

RPMI 1640 broth with L-glutamine without sodium bicarbonate and 0.165 µMOPS buffer (34.54 g/L) was used. The medium was adjusted to pH 7.0 at 25 ⁰C. Sterility control of each bottle was performed before it was used.

Antifungal agents

Terbinafine was provided by the manufacturer as a standard powder. All drugs were dissolved in 100% dimethyl sulfoxide according to the NCCLS methods^{10, 11} . The final drug concentrations were 32 to 0.01g/mL for all drugs.

Preparation of inoculum

The preparation of inoculum suspensions was based mainly on the NCCLS guidelines²¹ and as described previously¹²⁻¹⁴. For dermatophytes the final inoculum size was adjusted from 1.2 X10⁴ to 6 X10⁴ CFU/mL and for C. albicans it was approximately 1 X 10³ to 5 X 10³ CFU/mL^{10, 15, 16}.

Test Procedure

The test procedure was applied according to the NCCLS protocols^{10, 11}. Microdilution plates (96 U-shaped) were prepared and frozen at -70 ⁰C until needed. Each microdilution well containing 100 µL of the 2-fold drug concentration was inoculated with 100 µL of the final inoculum suspension. Two drug-free growth controls were included for each test plate, one without any drug (growth control) and the other with media containing an equivalent amount of solvent used to dissolve the drug (solvent control). For all drugs, the minimum inhibitory concentration (MIC) was defined as the lowest concentration showing 100% growth inhibition. All of the compounds (1a-6b) were found to have antifungal activity against M. gypseum, M. canis, T. mentagrophytes, T. rubrum and C. albicans. MIC values of the compounds are given in Table 4 and 5.

Table 4: Antifungal activity: MIC values (µg/mL) of compounds (1a-6a)

Compd	R	R’	M.gypseum NCPF-580	M.canis	T. megentag-rophytes	T. rubrum	C. albicans ATCC 10231
1a	CH3	N(CH3)2	7	7	8	8	14
2a	CH3	OCH3	–	–	–	–	–
3a	CH3	OH	–	–	–	–	–
4a	CH(CH3)2	N(CH3)2	4	4	4	4	10
5a	CH(CH3)2	OCH3	6	6	6	6	6
6a	CH(CH3)2	OH	–	–	–	–	15
Terbinafine			< 0.25	< 0.25	< 0.25	< 0.25	1

 

Table  5: MIC values (µg/mL) of compounds (1b-6b)

Compd	R	R’	M.gypseum NCPF-580	M.canis	T .megentag-rophytes	T. rubrum	C. albicans ATCC 10231
1b	CH3	N(CH3)2	3	5	5	5	5
2b	CH3	OCH3	4	5	5	2	5
3b	CH3	OH	3	3	3	3	5
4b	CH(CH3)2	N(CH3)2	3	3	3	3	8
5b	CH(CH3)2	OCH3	5	4	3	2	8
6b	CH(CH3)2	OH	4	4	4	4	5
Terbinafine			< 0.25	< 0.25	< 0.25	< 0.25	1

 

Results

All the synthesized compounds were confirmed by spectral data and then screened for antibacterial activity against Staphylococcus aureus (ATCC 6538), E. coli (ATCC 8739) and Bacillus subtilis (MTCC441) and for antifungal activity against M. gypseum (NCPF-580), M. canis, T. megenagrophytes, T. rubrum and C.albicans (ATCC 10231). All compounds have shown good activity when compared with standard drug ampicillin.

Compounds 2a, 3a and 6a has no antifungal activity while (1b-6b) have shown the significant antifungal activity when compared with standard drug terbinafine. The in vitro antibacterial and antifungal activities are presented in Table 2, 3, 4 and 5.

Discussions

The antibacterial activity of all the synthesized compounds are good enough in comparison to ampicillin while the antifungal activity of thiosemicarbazone derivatives of piperidin-4-one are very high from piperidine-4-one which indicate the activity is enhanced by addition of this group.

Conclusion

The present study reveals that these compounds could be used as a template for the future development through modification or derivatization to design more potent antimicrobial and antifungal agents with fewer side effects.

References

1. Laurence D. R., Bennet P. N., Clinical Pharmacology., 7^th edition, ELBS, 149.
2. Kalaiselvan R., Sathyamurthy D., Mohanta G. P., and Uma Devi S., Synthesis, Antimicrobial and Analgesic studies of N-nitroso-2, 6-di-p-anisyl-piperidin-4-ones. Indian Drugs., 2004, 41 ( 5 ), 258-261.
3. Ramalingan C, Park Y T, Kabilan S., Synthesis, Stereochemistry and Antimicrobial evaluation of substituted piperidin-4-one oxime ethers. Eur J Med Chem., 2006.
4. Balasubramanian S., Aridoss G., Parthian P., Synthesis and biological evaluation of novel benzimidazol/benzoxazolylethoxypiperidone oximes. Pharm. Bull., 2006, 125-30.
5. Murugesan S., Perumal S., and Selvaraj S., Synthesis, stereochemistry, and antimicrobial activity of 2,6-diaryl-3-(arylthio)piperidin-4-ones. Chem Pharm Bull (Tokyo)., 2006, 54: 795-801.
6. Manimekalai A., Jayabharathi J., Rufina L., and Mahendhiran R., stereo chemical studies of some t-3- methyl-r-2, c-6- diphenylpiperidin-4-one azine derivatives. Indian J. Chem., 2003, 42 B, 2074-2079.
7. Noller C. R., and Baliah V., The Preparation of Some Piperidine Derivatives by the Mannich Reaction. Am. Chem. Soc., 1948, 3853.
8. Kuppuswamy A., Shanmuga Pandiyan P., and Veenaa A., Antifungal Activity of Newly synthesized Piperidin-4-oxime Derivatives. Indian Drugs., 2003, 41 (1), 7-11.
9. Pandeya S. N., Smitha S., Jyoti M., Sridhar S. K: Biological activities of isatin and its derivatives, Acta Pharm., 2005, 27-46.
10. National Committee for Clinical Laboratory Standards. (1997).
11. National Committee for Clinical Laboratory Standards. (1998).
12. Fernandez-Torres, F.J. Cabanes, A. Carilla-Munoz, A. Esteban, I. Inza, L. Abarca and 13. J. Guarro, J. Clinical Microbiol. 40, 3999-4003 (2002).
13. Fernandez-Torres, A.J. Carillo, E. Martin, A.D. Palacio, M.K. Moore, A. Valverde, M. Serrano and J.Guarro, Antimicrob. Agents Chemother. 45, 2524-2528 (2001).
14. K. Gupta and Y. Kohli, Brit. J. of Dermatol. 149, 296-305 (2003).
15. Espinel-Ingroff, C.W. Kigh, T.M. Kerkering, R.A. Famthing, K. Bartizal, J.N. Galgiani, K. Villareal, M.A.Pfaller, T. Gerarden, M.G. Rinaldi and A. Fathergill, Clin. Microbiol. 30, 3138-3145 (1992).
16. L. Rodriguez-Tudela, J. Berenguer, J.V. Martinez-Suarez and R. Sanchez, Antimicrob. Agents Chemother. 40, 1998-2003 (1996).